Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Hospira 4Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Hospira 4Q

Growth in the quarter was driven by an increase in Specialty Injectable Pharmaceuticals, with sales in the Americas up 27% to $439.2 million, in Europe, Middle East & Africa, sales were $76.7 million (+21%), and in the Asia Pacific region, sales were

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hospira 4Q

4Q Revenues: $1.1 billion (+16%)

4Q Earnings: $97.0 million (-8%)

FY Revenues: $3.9 billion (+7%)

FY Earnings: $403.9 million (+26%)

Comments: Growth in the quarter was driven by an increase in Specialty Injectable Pharmaceuticals, with sales in the Americas up 27% to $439.2 million, in Europe, Middle East & Africa, sales were $76.7 million (+21%), and in the Asia Pacific region, sales were $62.4 million (+25%). The company launched the generic chemotherapy agent oxaliplatin in the U.S. and sales of the sedation agent Precedex, continued to grow.

Click here to find out more about Hospira

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters